Patient’s consultation complaints and treatment expectations: Complaint: found HBsAg positive for more than 20 years, anti-HCV positive for 11 days Treatment expectations: worried about his condition, afraid of being sick for life like his father Patient’s basic situation and baseline characteristics: n Gender, age, economic situation, etc. Male, 41 years old, father also co-infected with hepatitis B and C n Baseline characteristics such as diagnosis, medical history, laboratory test results : l Diagnosis: chronic hepatitis B and C viral hepatitis co-infection l Medical history: more than 20 years of disease but no significant discomfort, no antiviral treatment, found anti-HCV positive for 11 days l Laboratory findings at presentation: virology: HBV DNA 3.07×105 IU/ml. HCV RNA-GT 2a, HCV-RNA 7.338×104 IU/ml; serology. HBsAg (+), HBeAg (+), HBcAb (+); biochemistry: ALT 43U/L, AST 28U/L, uric acid 442umol/L elevated Expert treatment and experience: The patient had no previous history of antiviral treatment, after giving pegylated glycol alpha-2a interferon and ribavirin, hepatitis C virus turned negative in 3 weeks; liver function was normal in 3 months, HBV DNA decreased to 6.21×104 IU/ml. 104 IU/ml, continued to apply interferon combined with ribavirin anti-hepatitis C virus treatment and added entecavir anti-hepatitis B virus treatment; treatment until 9 months, HBV-DNA was not detected, HBsAg turned negative, and achieved clinical cure of chronic hepatitis B. At this time, hepatitis C virus was negative. To ensure efficacy, the patient continues treatment with pegylated interferon in combination with ribavirin and entecavir and will be reviewed after 3 months (1 year of treatment). Long-acting interferon is the first-line treatment option for patients with chronic hepatitis B and is also the standard treatment component of hepatitis C treatment. This patient received long-acting interferon in combination with ribavirin and achieved good efficacy, with hepatitis C virus conversion at 3 months of treatment and HBsAg clearance at 9 months, reaching the treatment endpoint of clinical cure. However, in order to consolidate the efficacy and avoid relapse, such patients still need to complete the full course of treatment and should not stop the drug easily.